EUVIMEDEUVIMED entdecken
Beobachtungsstudie

Efficacy of leuprorelin in spinal and bulbar muscular atrophy: a 3-year observational study

Min-Gu Kang, Minsung Kang, Hee-Jin Cho, Yu-Sun Min, Jin-Sung Park

Neurological Sciences · 2024

DOI: 10.1007/s10072-024-07410-1 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Neurological Sciences, 2024. Verfasst von Min-Gu Kang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rehabilitation Medicine, Kyungpook National University, Kyungpook National University Hospital, Daegu, South Korea. Hauptthemen laut MEDLINE: Leuprolide. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: This study aimed to investigate the long-term effects and functional outcomes of androgen suppression therapy using leuprorelin among Korean patients with spinal and bulbar muscular atrophy (SBMA). METHODS: This observational study enrolled patients with genetically confirmed SBMA who provided informed consent. Leuprorelin was administered via subcutaneous injection every 12 weeks. The primary outcome measure was the change in total Spinal and Bulbar Muscular Atrophy Functional Rating Scale (SBMAFRS) scores. RESULTS: A total of 48 SBMA patients were evaluated in this study. Among them, 39 patients underwent androgen suppression therapy over a 3-year period. The total SBMAFRS score decreased from 41.72 ± 5.55 to 36.74 ± 7.74 (p < 0.001) in patients who completed their treatment. The subgroup with a baseline SBMAFRS score of ≥ 42 had a significantly lower decline in SBMAFRS score than did those with a baseline SBMAFRS score of ≤ 41. We determined that at a baseline, SBMAFRS cutoff value of 41.5 could predict good prognosis, with a corresponding area under the curve of 0.689. CONCLUSION: Despite androgen suppression therapy, all enrolled participants exhibited a decrease in the overall SBMAFRS score. However, those with a baseline SBMAFRS of ≥ 42 showed a mild decrease in scores, indicating a more favorable prognosis. These findings suggest that a higher baseline motor function was a key prognostic indicator in SBMA treatment and that initiating early leuprorelin treatment in patients with high baseline function may lead to good clinical outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LeuprolideHumansMaleMiddle AgedTreatment OutcomeFemaleAgedAdultAndrogen AntagonistsMuscular Atrophy, SpinalBulbo-Spinal Atrophy, X-LinkedSeverity of Illness Index

Stichwörter der Autor:innen

Bulbo-spinal atrophy, X-linkedDeglutition disordersLeuprolide

Substanzen

LeuprolideAndrogen Antagonists

Autor:innen und Institutionen

  • Department of Rehabilitation Medicine, Kyungpook National University, Kyungpook National University Hospital, Daegu, South Korea.
  • Department of Neurology, School of Medicine, Kyungpook National University, Kyungpook National University Chilgok Hospital, Daegu, South Korea.
  • Department of Rehabilitation Medicine, School of Medicine, Kyungpook National University, Kyungpook National University Chilgok Hospital, Daegu, South Korea.
  • Department of Neurology, School of Medicine, Kyungpook National University, Kyungpook National University Chilgok Hospital, Daegu, South Korea. neurojspark@gmail.com.
  • Brain Science & Engineering Institute, Kyungpook National University, Daegu, South Korea. neurojspark@gmail.com.

Zitieren

APA

Kang, M. G., Kang, M., Cho, H. J., Min, Y. S., & Park, J. S. (2024). Efficacy of leuprorelin in spinal and bulbar muscular atrophy: a 3-year observational study. Neurological Sciences. https://doi.org/10.1007/s10072-024-07410-1

Vancouver

Kang MG, Kang M, Cho HJ, Min YS, Park JS. Efficacy of leuprorelin in spinal and bulbar muscular atrophy: a 3-year observational study. Neurological Sciences. 2024. doi:10.1007/s10072-024-07410-1

BibTeX
@article{Kang2024,
  author = {Kang, Min-Gu and Kang, Minsung and Cho, Hee-Jin and Min, Yu-Sun and Park, Jin-Sung},
  title = {Efficacy of leuprorelin in spinal and bulbar muscular atrophy: a 3-year observational study},
  journal = {Neurological Sciences},
  year = {2024},
  doi = {10.1007/s10072-024-07410-1}
}
Kostenlos starten →